DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.


Contact Us

We invite you to learn more about CorMedix and submit your business opportunity by sending an email to Business Development by clicking here.

CorMedix is seeking to partner with companies to expand the potential uses of taurolidine, based on its broad antimicrobial, anti-inflammatory, and potential antineoplastic properties.

CorMedix believes that collaboration with other companies that share our goal of improving outcomes can create significant value.